Lutheran Hospital
Lutheran Hospital was paid $41.49M by Medicaid between Jan 2018 and Dec 2024, across 331 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 18% of everything it billed.
CLEVELAND, OH 44113
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,094 | $3.10M | |
| 2019 | 94,268 | $3.47M | |
| 2020 | 73,164 | $4.22M | |
| 2021 | 97,607 | $5.19M | |
| 2022 | 96,681 | $4.46M | |
| 2023 | 304,563 | $12.23M | |
| 2024incomplete | 248,841 | $8.83M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 25,221 | 20,025 | $7.49M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 49,394 | 45,240 | $5.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 42,019 | 36,887 | $5.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 45,833 | 42,876 | $5.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 23,755 | 10,053 | $1.58M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.8% | 9,870 | 8,509 | $1.14M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.7% | 14,700 | 11,643 | $1.14M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 3,707 | 3,154 | $993K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 6,728 | 6,078 | $958K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 3,388 | 2,793 | $836K |
| 27447 | 1.9% | 278 | 208 | $779K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 3,642 | 3,239 | $614K |
319 more codes
| G0378 | Hospital observation service, per hour | 1.4% | 7,297 | $573K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 4,553 | $524K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 3,896 | $486K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 4,653 | $448K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 2,332 | $437K |
| C1776 | Joint device (implantable) | 1.0% | 734 | $430K |
| 80053 | Comprehensive metabolic panel | <1% | 55,736 | $404K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,066 | $378K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,563 | $350K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,009 | $276K |
| 90870 | <1% | 1,034 | $226K | |
| 64483 | <1% | 549 | $204K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17,342 | $195K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,065 | $186K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 873 | $182K |
| 90839 | <1% | 1,491 | $168K | |
| 70498 | <1% | 570 | $154K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 7,889 | $149K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,679 | $133K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,402 | $121K |
| 73564 | <1% | 2,499 | $110K | |
| 93975 | <1% | 1,031 | $110K | |
| 97161 | <1% | 3,810 | $101K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,301 | $101K |
| 76770 | <1% | 658 | $92K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,257 | $91K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 210 | $89K |
| 84439 | <1% | 3,816 | $86K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,937 | $81K |
| 84484 | <1% | 24,896 | $77K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,657 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,892 | $72K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,389 | $70K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,043 | $68K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,920 | $67K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,043 | $66K |
| 87631 | <1% | 498 | $64K | |
| 93971 | <1% | 1,013 | $61K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 234 | $59K |
| 80061 | Lipid panel | <1% | 4,844 | $57K |
| 93970 | <1% | 411 | $55K | |
| 64447 | <1% | 406 | $55K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,128 | $53K |
| 11045 | <1% | 262 | $52K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,058 | $51K |
| 97165 | <1% | 1,239 | $50K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,142 | $49K |
| 27130 | <1% | 22 | $46K | |
| 81513 | <1% | 390 | $45K | |
| 70491 | <1% | 133 | $42K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 399 | $42K |
| 73130 | <1% | 1,899 | $42K | |
| 73030 | <1% | 1,756 | $41K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 259 | $39K |
| 97802 | <1% | 554 | $38K | |
| 73502 | <1% | 1,240 | $36K | |
| 97803 | <1% | 464 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,588 | $33K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 163 | $33K |
| 86850 | <1% | 1,613 | $33K | |
| 85027 | <1% | 19,000 | $32K | |
| 71250 | <1% | 385 | $31K | |
| 96367 | <1% | 834 | $29K | |
| 97116 | <1% | 1,439 | $27K | |
| 72100 | <1% | 1,272 | $27K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,217 | $26K |
| 12001 | <1% | 172 | $26K | |
| 93799 | <1% | 4,484 | $25K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,819 | $24K |
| 73630 | <1% | 1,601 | $24K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 78 | $24K |
| 73562 | <1% | 465 | $23K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,763 | $23K |
| 10060 | <1% | 121 | $19K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,181 | $19K |
| 86803 | <1% | 879 | $19K | |
| 72131 | <1% | 380 | $18K | |
| 80320 | <1% | 1,951 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,578 | $18K |
| 83735 | <1% | 17,651 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 121 | $18K |
| 76536 | <1% | 198 | $17K | |
| 86900 | <1% | 1,634 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,888 | $16K |
| 82728 | <1% | 1,185 | $15K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 887 | $15K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 333 | $15K |
| 73110 | <1% | 1,012 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,456 | $14K |
| 82962 | <1% | 11,305 | $13K | |
| 82607 | <1% | 1,007 | $13K | |
| 81001 | <1% | 46,679 | $13K | |
| 93017 | <1% | 231 | $13K | |
| 97162 | <1% | 304 | $13K | |
| 73610 | <1% | 1,264 | $12K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 676 | $12K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 76 | $12K |
| 73560 | <1% | 909 | $12K | |
| 70486 | <1% | 515 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 782 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,298 | $11K |
| 86780 | <1% | 2,781 | $11K | |
| 83540 | <1% | 1,307 | $10K | |
| 85610 | <1% | 5,317 | $10K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 566 | $10K |
| 84702 | <1% | 1,618 | $10K | |
| 76857 | <1% | 1,007 | $9K | |
| 90715 | <1% | 735 | $9K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 335 | $9K |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 1,168 | $9K |
| 82805 | <1% | 383 | $9K | |
| 87340 | <1% | 662 | $8K | |
| 86140 | <1% | 1,220 | $8K | |
| 83550 | <1% | 1,280 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 325 | $7K |
| 86901 | <1% | 1,633 | $7K | |
| 74183 | <1% | 30 | $7K | |
| 72050 | <1% | 159 | $7K | |
| 82570 | <1% | 828 | $7K | |
| 0001A | <1% | 169 | $6K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 54 | $6K |
| 70496 | <1% | 597 | $6K | |
| 85379 | <1% | 4,563 | $6K | |
| 00104 | <1% | 1,012 | $6K | |
| 84100 | <1% | 2,001 | $6K | |
| 0002A | <1% | 150 | $6K | |
| 96376 | <1% | 2,608 | $6K | |
| 83970 | <1% | 315 | $5K | |
| 73080 | <1% | 499 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,687 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 34 | $5K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,239 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 530 | $5K |
| 86706 | <1% | 385 | $5K | |
| 80076 | <1% | 528 | $5K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $5K |
| 76642 | <1% | 42 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,100 | $4K |
| 96368 | <1% | 121 | $4K | |
| 82077 | <1% | 4,723 | $4K | |
| 83880 | <1% | 2,313 | $4K | |
| 74018 | <1% | 252 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,228 | $4K |
| 76942 | <1% | 184 | $4K | |
| 80197 | <1% | 252 | $4K | |
| 81025 | <1% | 20,767 | $4K | |
| 82043 | <1% | 614 | $4K | |
| 76801 | <1% | 453 | $3K | |
| 80069 | <1% | 282 | $3K | |
| 73700 | <1% | 25 | $3K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 266 | $3K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 27 | $3K |
| 82550 | <1% | 3,546 | $3K | |
| 76882 | <1% | 30 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 856 | $3K |
| 87077 | <1% | 1,561 | $3K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 13 | $3K |
| 73590 | <1% | 431 | $3K | |
| 99307 | <1% | 520 | $3K | |
| J3490 | Unclassified drugs | <1% | 514 | $3K |
| 74022 | <1% | 339 | $3K | |
| 82553 | <1% | 173 | $2K | |
| 73140 | <1% | 323 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 79 | $2K |
| 73221 | <1% | 12 | $2K | |
| 86703 | <1% | 2,221 | $2K | |
| 83690 | <1% | 10,680 | $2K | |
| 72110 | <1% | 59 | $2K | |
| 99225 | <1% | 142 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 709 | $2K |
| 82977 | <1% | 160 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,369 | $2K |
| 73523 | <1% | 39 | $2K | |
| 94660 | <1% | 20 | $2K | |
| 86704 | <1% | 137 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 28 | $2K |
| 72072 | <1% | 124 | $2K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 35 | $2K |
| 73090 | <1% | 291 | $2K | |
| 71101 | <1% | 207 | $2K | |
| 72040 | <1% | 41 | $1K | |
| 85652 | <1% | 610 | $1K | |
| 80365 | <1% | 149 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 211 | $1K |
| 85730 | <1% | 1,810 | $1K | |
| 84550 | <1% | 357 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 73 | $1K |
| 77080 | <1% | 26 | $1K | |
| 82746 | <1% | 390 | $1K | |
| 87481 | <1% | 288 | $1K | |
| 87186 | <1% | 1,257 | $1K | |
| 72128 | <1% | 21 | $1K | |
| 76870 | <1% | 89 | $1K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 12 | $1K |
| 84132 | <1% | 807 | $1K | |
| 84156 | <1% | 339 | $989.11 | |
| 87430 | <1% | 2,540 | $963.84 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 30,390 | $952.49 |
| 84153 | <1% | 61 | $939.90 | |
| 82947 | <1% | 507 | $924.01 | |
| Q3014 | Telehealth originating site facility fee | <1% | 33 | $879.37 |
| 11043 | <1% | 16 | $873.79 | |
| 82330 | <1% | 474 | $754.87 | |
| A9270 | Non-covered item or service | <1% | 2,762 | $714.37 |
| 73070 | <1% | 12 | $683.72 | |
| 87070 | <1% | 571 | $682.13 | |
| 83605 | <1% | 1,902 | $650.42 | |
| 87205 | <1% | 728 | $626.47 | |
| 86431 | <1% | 54 | $589.32 | |
| 80164 | <1% | 235 | $560.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,279 | $558.52 |
| 84165 | <1% | 88 | $554.02 | |
| 84703 | <1% | 1,343 | $520.51 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $471.21 |
| 85018 | <1% | 484 | $447.15 | |
| 87040 | <1% | 782 | $440.13 | |
| 74019 | <1% | 61 | $417.86 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,516 | $379.80 |
| 84155 | <1% | 111 | $376.73 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,263 | $374.08 |
| 90714 | <1% | 34 | $340.09 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,538 | $309.26 |
| 86038 | <1% | 16 | $304.31 | |
| 82533 | <1% | 20 | $303.40 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 363 | $301.22 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,086 | $291.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 916 | $283.52 |
| 87640 | <1% | 17 | $277.52 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 26 | $255.86 |
| 83615 | <1% | 62 | $230.33 | |
| 84481 | <1% | 44 | $229.55 | |
| 86160 | <1% | 19 | $229.02 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 820 | $218.66 |
| 86480 | <1% | 14 | $188.22 | |
| 99152 | <1% | 603 | $183.34 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 412 | $166.44 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 31 | $165.54 |
| 87641 | <1% | 17 | $163.82 | |
| 82435 | <1% | 394 | $161.85 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 55 | $155.76 |
| 87808 | <1% | 234 | $150.39 | |
| 82375 | <1% | 565 | $128.05 | |
| 82042 | <1% | 14 | $127.14 | |
| 72170 | <1% | 196 | $123.98 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,175 | $117.77 |
| 82784 | <1% | 35 | $99.79 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,887 | $99.75 |
| 73660 | <1% | 16 | $99.23 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,069 | $99.14 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,520 | $96.45 |
| 86308 | <1% | 26 | $95.23 | |
| 84295 | <1% | 391 | $93.42 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 835 | $92.47 |
| 85045 | <1% | 51 | $83.69 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 127 | $81.02 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 1,071 | $77.86 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,454 | $77.25 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 182 | $73.29 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 54 | $71.86 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $69.90 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,415 | $69.81 |
| 82010 | <1% | 245 | $66.70 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 328 | $66.58 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,009 | $65.45 |
| 84145 | <1% | 37 | $64.71 | |
| 80143 | <1% | 55 | $64.45 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,670 | $63.46 |
| 83050 | <1% | 390 | $61.30 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 33 | $58.74 |
| 86592 | <1% | 45 | $58.70 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,047 | $53.48 |
| 94644 | <1% | 28 | $52.48 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,918 | $52.12 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 731 | $46.42 |
| 86705 | <1% | 14 | $45.49 | |
| 83521 | <1% | 19 | $43.95 | |
| 94760 | <1% | 3,465 | $39.40 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 331 | $39.22 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,133 | $36.95 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 195 | $32.31 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 220 | $32.26 |
| 87899 | <1% | 14 | $31.33 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,243 | $30.90 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 591 | $27.85 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 552 | $21.35 |
| 87088 | <1% | 59 | $19.43 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $18.26 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 165 | $17.94 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 805 | $17.08 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 505 | $12.36 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 88 | $11.20 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 463 | $10.82 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 38 | $7.98 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 73 | $5.29 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 16 | $5.02 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 34 | $4.80 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 35 | $4.54 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 55 | $3.31 |
| 91300 | <1% | 319 | $3.08 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 36 | $3.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,245 | $2.67 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 409 | $2.55 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 362 | $1.55 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 226 | $0.00 |
| 01402 | 0% | 280 | $0.00 | |
| 76376 | 0% | 66 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 23 | $0.00 |
| 01810 | 0% | 14 | $0.00 | |
| 82272 | 0% | 34 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 24 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 12 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 69 | $0.00 |
| 74174 | 0% | 13 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 197 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 182 | $0.00 |
| 87081 | 0% | 56 | $0.00 | |
| 01214 | 0% | 22 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 31 | $0.00 |
| 88304 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.